Ocera Therapeutics Announces Publication of Promising

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Ocera Therapeutics Announces Publication of Promising Preclinical Data in Support of Its Ammonia Scavenger OCR-002 in the Journal of Hepatology

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., April 11, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ: OCRX ), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced the publication of promising preclinical data related to the Company’s investigational drug candidate ornithine phenylacetate, OCR-002. The paper, entitled “ Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension ” is published in the April 2016 issue of the Journal of Hepatology ( http://www.journal-of-hepatology.eu/article/S...1/abstract ).

In this investigator-sponsored preclinical study, the authors investigated the role of ammonia in modulating human hepatic stellate cell (hHSC) activation in vitro and in vivo , and the ability of OCR-002 to lower ammonia and thus reduce resultant portal hypertension in bile duct ligated (BDL) rats, a model of cirrhosis. Portal hypertension, a complication of cirrhosis, is an increase in the blood pressure within a system of veins called the portal venous system.

Researchers subjected hHSCs to an ammonia challenge and results showed that pathophysiologic ammonia concentrations in vitro induced significant alterations in cellular morphology and caused significant and reversible changes in cell proliferation, metabolic activity, pro-inflammatory gene expression and activation markers. During the in vivo phase of the study, ammonia levels and portal pressure were compared in BDL rats vs. sham-operated controls prior to and after 5 days of treatment with OCR-002. Ammonia concentrations were significantly elevated in plasma in BDL rats compared to sham-operated rats (182 vs. 62.5μM, P < .0001), which decreased significantly following treatment with OCR-002 (83.8μM, P < .0001). These significant changes in plasma ammonia were correlated with alterations in portal pressure, which were significantly higher in BDL rats compared to sham (14 vs. 5.5mmHg, P < .0001). Ammonia lowering following administration of OCR-002 resulted in a significant reduction in portal pressure compared to BDL saline-treated rats (11mmHg, P < .01).

“The data clearly showed that increasing concentrations of ammonia were associated with marked structural and functional changes of hHSCs and that these effects were reversible when ammonia was removed from the medium and cells were allowed to recover,” said lead author Professor Rajiv Jalan, M.B.B.S, M.D. Ph.D., from the University College London. “Further, the reduction in ammonia concentration using OCR-002 resulted in a downregulation of HSCs activation markers that coincided with a significant reduction in portal pressure, providing a potential novel strategy to treat portal hypertension.”

“We are very encouraged by the study’s further findings supporting the ammonia-lowering properties of OCR-002 and its potential as a new therapy for hyperammonemic-implicated indications where current treatments are limited and or lack efficacy,” said Stan Bukofzer, M.D., Ocera’s Chief Medical Officer. “While Ocera remains focused on developing OCR-002 to potentially treat hepatic encephalopathy in patients with liver cirrhosis and acute liver failure, we believe that portal hypertension may, in the future, provide an additional clinical development opportunity for OCR-002 based on these early results.”

About Portal Hypertension

Portal hypertension, a complication of liver cirrhosis, is an increase in the blood pressure within a system of veins called the portal venous system. Veins coming from the stomach, intestine, spleen, and pancreas merge into the portal vein, which then branches into smaller vessels and travels through the liver. If the vessels in the liver are blocked due to liver damage, blood cannot flow properly through the liver. As a result, high pressure in the portal system develops. This increased pressure in the portal vein may lead to the development of large, swollen veins (varices) within the esophagus, stomach, rectum, or umbilical area (belly button). Varices can rupture and bleed, resulting in potentially life-threatening complications.

About Hepatic Encephalopathy

Hepatic encephalopathy is a debilitating and progressive complication of liver cirrhosis or liver failure, marked by mental changes including confusion, impaired motor skills, disorientation, and in its more severe form, stupor, coma and even death.

About Ocera

Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy (HE) in patients with acute liver failure and acute-on-chronic liver disease.

Ocera's HE clinical development efforts include an ongoing Phase 2b clinical trial, STOP-HE, which is evaluating the safety and efficacy of intravenously-administered OCR-002 in resolving neurocognitive symptoms of acute HE in hospitalized patients with elevated ammonia, and a Phase 1 program evaluating the safety, tolerability and pharmacokinetics of orally-available OCR-002 for the prevention of HE. The Company expects to complete enrollment in the STOP-HE trial in the fourth quarter of 2016 with top-line data to be published soon thereafter. An additional Phase 1 study of oral OCR-002 will commence later this year after further formulation optimization. For additional information, please see www.ocerainc.com .

Forward-Looking Statements

This press release contains "forward-looking" statements, including, without limitation, all statements related to the OCR-002 clinical development program, including but not limited to the potential benefits of OCR-002 to help patients with hepatic encephalopathy, the potential benefits of OCR-002 to help patients with portal hypertension, the timing of clinical and enrollment milestones, and the timing of study data. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "expected," "hope," "plan," "potential," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Ocera's current expectations. Forward-looking statements involve risks and uncertainties and Ocera's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, including those risks and uncertainties discussed under the heading "Risk Factors" in Ocera's Annual Report on Form 10-K for the year ended December 31, 2015 and subsequent filings with the SEC. All information in this press release is as of the date of the release, and Ocera undertakes no duty to update this information unless required by law.

OCRX-G

Susan Sharpe Ocera Therapeutics, Inc. contact@ocerainc.com 919-328-1109

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Robert Half's Parent Support Earns Fortune Recognition

Updated Category News Views 92

A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...

Continue Reading
NextPlat’s 150-Patient Test Has a Long Road Ahead

Updated Category News Views 114

A strip of pills can look mundane, yet it is where this entire NextPlat pitch either earns its keep or falls apart. PharmcoRx has signed a partner pharmacy agreement with MedSure Systems for a 150-patient Medicare medication-adherence pilot in South Florida. That is a small starting line, no two ways around it. Still, the mechanics are more interesting than another vague...

Continue Reading
Holland America Puts 2028 Alaska Demand on Display

Updated Category News Views 156

Alaska’s interior is where a cruise brochure either earns its keep or gets exposed. Holland America Line is opening bookings for 2028 Alaska Cruisetours nearly two years ahead, tying a coast-and-land product to the reimagined Oosterdam’s Alaska debut. That is not merely another itinerary release. It is a fairly deliberate attempt to sell a bigger, longer and...

Continue Reading
Wenge AI Removes a Small Friction Point for ScienceOra

Updated Category News Views 31

Scientific software rarely loses users because the underlying model is too clever; it loses them because getting through the front door is a nuisance. Wenge AI has addressed that unglamorous problem by adding Google and Apple sign-in options to the international version of ScienceOra, its AI-powered research and decision-support platform. This is not the sort of...

Continue Reading
JDEnergy's RE+ Push Meets a Grid Hungry for Storage

Updated Category News Views 90

Certification Is Useful, Not a Victory Lap A battery box earning a safety certificate is not usually thrilling stuff, but the timing matters here. On Nov. 19, 2026, JDEnergy laid out its North American storage pitch at RE+ in Las Vegas while electricity demand is getting shoved higher by industrial buildout and AI data centers. Add more variable renewable generation to an...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 162

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading
SAP Execution Can Steady Operations Beyond Spreadsheets

Updated Category News Views 87

Spreadsheets breed little kingdoms, and SAP is often left outside the gate. That is the operational mess Martin Rowan, managing partner at Reveal USA, Inc. in Naperville, is taking aim at in a Nov. 19, 2026 HelloNation feature. His central point is not terribly glamorous, but it is dead right: a company gets less stable when it uses SAP to explain yesterday's results...

Continue Reading
LKQ’s Europe ERP Mess Turns Into a Credibility Test

Updated Category News Views 98

A software rollout should not be able to punch a company in the teeth twice, yet LKQ shareholders have watched precisely that ugly movie in 2026. The October 23 disclosure was a real gut-check: an immediate CEO departure, a $16 million net loss, and renewed acknowledgement that the German enterprise-resource-planning rollout was disrupting Europe. Shares fell $5.05, or...

Continue Reading
Huawei's Financial AI Push Targets Scale, Not Demos

Updated Category News Views 23

Banking AI has reached the point where a clever chatbot barely moves the needle. Huawei's message at Singapore FinTech Festival 2026 was aimed squarely at that harder, more expensive problem: turning AI from a scattered pilot project into machinery a financial institution can operate, govern, repeat, and improve without handing over its crown jewels. Ownership Is the...

Continue Reading
CMS Audit Proposal Reopens Medicare Advantage Risk

Updated Category News Views 44

A regulator just tossed a rusted anchor into managed care's earnings model. CMS's proposed Comprehensive Regulations to Uncover Suspicious Healthcare rule, dubbed CRUSH and numbered CMS-6098-P, puts Medicare Advantage risk-adjustment audits back at center stage. The headline nobody can casually wave away: audit findings from sampled enrollees could be extrapolated across...

Continue Reading

Top 5 Most Recently Viewed Articles

Dyne Therapeutics Faces Legal Inquiry Amid FDA Approval Delays

Updated Category News Views 189

Understanding the Investigation Surrounding Dyne Therapeutics Recently, Pomerantz LLP, a recognized law firm, initiated an investigation on behalf of investors of Dyne Therapeutics, Inc. (NASDAQ: DYN). The focus of this inquiry is on whether Dyne and its executives have participated in unlawful business practices, including securities fraud. These claims arise amidst...

Continue Reading
ThermAI Secures Major Investment from Tech Visionary Daniel Keller

Updated Category News Views 334

ThermAI's Innovative Breakthrough in Heat Recovery Technology ThermAI, a groundbreaking decentralised compute and heat-recovery protocol, has recently secured a strategic investment from Daniel Keller, a prominent figure in the tech industry known for co-founding Flux and playing a pivotal role in architecting Zelcore. This partnership is set to expedite ThermAI's...

Continue Reading
CAPTRUST Expands Reach with Carolinas Investment Consulting

Updated Category News Views 119

CAPTRUST Welcomes Carolinas Investment Consulting CAPTRUST Financial Advisors, known for their commitment to excellent service in the financial advisory realm, is embracing a new chapter with the addition of Carolinas Investment Consulting (CIC). This collaboration aims to deliver enhanced investment consulting and financial planning services to an even broader clientele....

Continue Reading
Essential Vehicle Preparations for College Students

Updated Category News Views 141

Get Your Car Ready for College Mercury Insurance Provides a Checklist to Make Sure You're Prepared As the academic year approaches, it's that time when students gear up to head back to campus. Whether you're a parent assisting your child or a student planning to drive yourself, it's crucial to ensure that your vehicle is ready for the journey ahead. Understanding this...

Continue Reading
Cineverse Unveils cineSearch: Revolutionizing Streaming Search

Updated Category News Views 406

Cineverse Introduces cineSearch for Enhanced Content Discovery AI-Powered cineSearch Unlocks Personalized Content Recommendations Across Leading Streaming Platforms Cineverse Corp. (NASDAQ: CNVS), an innovative streaming technology and entertainment company, is excited to announce the public preview of cineSearch, its groundbreaking AI-driven content discovery tool....

Continue Reading